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We used insulin pump therapy in three patients (two males and one female; age 5.5, 21 and 28.2 years, respectively) with CFRD and we
reported the experience of 2 years of follow-up.
In all the patients during the CSII treatment, the annual mean level of HbA1c reduced and the annual mean level of BMI increased,
respected, the year before starting the CSII (in MDI treatment with 4 injections/day). The insulin requirements decreased during the CSII
treatment and respected MDI treatment. During the CSII treatment, none of the patients exhibited episodes of DKA or severe hypoglycaemia.
Only two episodes of lipohypertrophy and a slight local cutaneous inflammation were reported.
Conclusions: The use of CSII in our patients with CFRD improves the metabolic control of diabetes and the nutritional status with no
concomitant problems related to this treatment.
© 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: CFRD; Insulin pump therapy; CSII; Insulin treatment; Children1. Introduction
With improvement in clinical management, the life ex-
pectancy of CF patients has increased dramatically in recent
years [1]. Other long-term complications have become
apparent as more patients with cystic fibrosis survive into
adulthood. The most significant of these complications is
cystic fibrosis-related diabetes (CFRD) which appears in
10–25% of individuals with cystic fibrosis [2,3]. DM in CF
exhibits different clinical characteristics in comparison with
type 1 and type 2 diabetes [4]. As this is an insulinopenic
condition, at present, insulin treatment is the only medical
therapy officially recommended for CFRD [5]. GoodAbbreviations: CF, cystic fibrosis; CFRD, cystic fibrosis-related diabetes;
DM, diabetes mellitus; CSII, continuous subcutaneous insulin infusion; MDI,
multiple daily injection; HbA1c, haemoglobin A1c; BMI, body mass index;
DKA, diabetic ketoacidosis; R, short-acting regular insulin; NPH, intermedi-
ate-acting insulin.
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doi:10.1016/j.jcf.2006.07.005glycometabolic control is important not only to improve
the clinical and nutritional status of these patients, but also to
prevent or delay the appearance of long-term microvascular
complications linked to the diabetic disease [6,7].
Continuous subcutaneous insulin infusion (CSII) is being
increasingly adopted in adults and children affected by type
1 diabetes, where it has been shown to be a valid alternative
to multiple daily injections (MDI) and able to improve gly-
cometabolic control and the quality of life of these patients
[8,9]. There are few references in literature regarding the use
of this therapy in patients affected by cystic fibrosis-related
diabetes [10,11]. At our centre, we used CSII in three pa-
tients with CFRD and we report below the experience of
2 years of follow-up.
2. Patient report 1
A 7.5-year-old male with Cystic Fibrosis, diagnosed at
2 months of age (sweat test: Cl=88 meq/l) and CFRD diag-
nosed at 3.5 years of age, started the insulin pump therapy (H-ed by Elsevier B.V. All rights reserved.
Fig. 2. Annual mean values of BMI in the year pre-CSII and the 2 years of
CSII treatment.
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acting insulin analogue (Aspart, Novonordisk).
Insulin therapy was started at the diagnosis of CFRD, and
in the year before CSII therapy, the patient was receiving
4 insulin injections/day as follows: a regular (R) insulin and
an intermediate (NPH) insulin before breakfast, a rapid-
acting insulin analogue before lunch and dinner, an NPH
insulin at bed-time.
The annual mean level of HbA1c in the year before
starting CSII (measured every 3 months) was 9.5% while
HbA1c at the start of this therapy (baseline) was 9.7%. The
annual mean level of HbA1c decreased during the years of
CSII treatment (7.9% in the first year and 8% in the second
year of CSII treatment) (Fig. 1).
The annual mean level of body mass index (BMI) (mea-
sured every 3 months), which was 15.1 in the year preceding
the start of CSII, increased during insulin pump treatment
(respectively, 15.6 in the first year of therapy with CSII and
15.8 in the second year) (Fig. 2). The BMI level at the start
of CSII (baseline) was 14.9.
Compared to insulin requirement (0.69 U/kg/day) prior to
CSII treatment, the insulin requirement decreased to 0.47, 0.51
and 0.49U/kg/day at 1, 12 and 24months after CSIIwas started.
Basal insulin made up 44–51% of the daily quantity of
insulin (44% at the first month, 51% at the 12th month and
50% at the 24th month of insulin pump therapy). Basal
nocturnal insulin made up around 9–11% of the total basal
(10% at the first month, 9% at the 12th month and 11% at the
24th month) (Table 1).
During the 2 years of CSII therapy, no episodes of diabetic
ketoacidosis (DKA) or severe hypoglycaemia (defined as any
hypoglycemic event requiring assistance from another person
or resulting in seizure or coma) occurred; there was one
episode of mild lipohypertrophy of the glutei (insertion site of
the cannula) and one episode of slight cutaneous inflamma-
tion which needed no local antibiotic treatment.
3. Patient report 2
A female of 32.3 years with CF which was diagnosed at
4 years of age. At 23.2 years of age, CFRD was diagnosedFig. 1. Annual mean values of HbA1c in the year pre-CSII and the 2 years of
CSII treatment.and began oral hypoglycemic treatment (Glibenclamide).
After 2 years of treatment with oral diabetes agent, she started
insulin therapy with 4 injections/day.
Insulin pump therapy (Minimed 508) was started using
rapid-acting insulin analogues (Humalog, Elly-Lilly) at the
age of 28.2 years. Before starting the CSII therapy, the
treatment was as follows: an R insulin before breakfast, lunch
and dinner and an NPH insulin at bed-time.
During insulin pump treatment there was a reduction in
the annual mean level of HbA1c: 7.8% in the year preceding
CSII, 6.2% and 6.4% in the first and second year of CSII
treatment. The HbA1c level was 7.6% at the star of CSII
treatment (Fig. 1).
The increase in the annual mean level of BMI (measured
every 3 months) indicates an improvement in the nutritional
state (20.1% in the year preceding CSII, 21.9 in the first year
of CSII and 22.1 in the second year). At the start of CSII, the
BMI level was 20.0 (Fig. 2).
The insulin requirement decreased from 0.82 U/kg/day
before CSII to 0.47 U/kg/day at 1 month (basal/bolus 50%/
50%, nocturnal basal 13% of total basal), 0.35 U/kg/day at
12 months (basal/bolus 40/60%, nocturnal basal 18% of total
basal), 0.40 U/kg/ day at 24 months of CSII (basal/bolus 52/
48%, nocturnal basal 12% of total basal) (Table 1).
During the 2 years of treatment, there were no episodes of
diabetic ketoacidosis (DKA), severe hypoglycemia or
cutaneous infection at the infusion site. During the first
year of CSII, there was one episode of lipohypertrophy on
the abdomen (insertion site of the cannula).
4. Patient report 3
A 23.1-year-old male was diagnosed with CF at 4 years of
age. A diagnosis of CFRD was made at 14.2 years of age and
insulin therapy was started with 4 injections/day.
At the age of 21 years, insulin pump therapy (H-Tron
plus, Disetronic) was started using rapid-acting insulin ana-
logues (Aspart, Novonordisk). In the year before CSII treat-
ment, the insulin therapy was as follows: a rapid-acting
insulin analogues before breakfast and dinner, a rapid-acting
Table 1
Insulin requirements, basal/bolus report and nocturnal basal prior and during the CSII treatment
Pre-CSII 1 month after starting CSII 12 months after starting CSII 24 months after starting CSII
Insulin
requirement
(U/kg/day)
Insulin
requirement
(U/kg/day)
Basal/
bolus
(%)
Nocturnal
basal
(%)
Insulin
requirement
(U/kg/day)
Basal/
bolus
(%)
Nocturnal
basal
(%)
Insulin
requirement
(U/kg/day)
Basal/
bolus
(%)
Nocturnal
basal
(%)
Patient 1 0.69 0.47 44/56 10 0.51 51/49 9 0.49 50/50 11
Patient 2 0.82 0.47 50/50 13 0.35 40/60 18 0.40 52/48 12
Patient 3 1.41 0.72 48/52 13 0.93 38/62 14 0.87 50/50 12
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insulin at bed-time.
During the 2 years of CSII treatment, the annual mean
HbA1c level decreased compared to the year preceding CSII
(7.2% in the first year of CSII and 7.1% in the second year
vs. 9.3% in the year before CSII). At the beginning of CSII,
HbA1c was 9.8% and 8.8% after 3 months (Fig. 1).
The annual mean BMI level increased both in the first and
second year of CSII when compared to the year preceding
insulin pump treatment (21.2 in the year before CSII, 22.8 in
the first year and 22.6 in the second year of CSII) (Fig. 2).
Insulin requirements decreased from 1.41 U/kg/day
before starting CSII to 0.72 U/kg/day in the first month of
CSII (basal/bolus 48/52%, nocturnal basal 13% of total
basal), 0.93 U/kg/day at 12 months (basal/bolus 38/62%,
nocturnal basal 14% of total basal) and 0.87 U/kg/day at
24 months of CSII (basal/bolus 50/50%, nocturnal basal 12%
of total basal) (Table 1).
There were no episodes of DKA, severe hypoglycemia,
local lipohypertrophy or local skin infections during CSII
treatment.
5. Discussion
The achievement and maintenance of a good metabolic
control through insulin therapy is an important objective in
the treatment of patients affected by CFRD for a variety of
reasons: some studies have reported an association between
hyperglycaemia and an increase in morbidity and mortality
in these patients [12,13]; with the increase in life expectancy,
literature increasingly reports the possibility of the onset and
progression of microvascular complications in the CFRD
population [6,14]. Besides controlling the glucidic metabo-
lism, insulin also plays an important role in maintaining a
normal body protein status. In patients affected by cystic
fibrosis, where there is an increase in protein catabolism,
insulin insufficiency could contribute to the worsening of the
nutritional state and more generally to deterioration in the
base illness [15,16].
The use of insulin pumps in all three patients resulted in a
significant reduction (between 1.2% and 1.7%) in the HbA1c
value, when compared to multiple daily injections (MDI)
which the patients had received in their preceding treatment.
This reduction remained more or less constant over the
2 years of therapy with CSII, thus demonstrating that thistreatment produced good glycometabolic control in both the
short and long term.
The increase in the BMI shows that weight increase and
more generally that the nutritional state of these patients
improved during insulin pump treatment. In guaranteeing
good nutritional status, which is a fundamental condition for
survival and for the good clinical status of CF patients, the
insulin pump offers the following advantages in addition to
improving glycaemic control: flexibility in the number,
timing and quantity of the meals, without having to resort to
additional injections; better management of the length of the
meals; improved adjustment of the quantity of insulin to the
glucidic input (thanks also to using only rapid-acting insulin
analogues); a more precise basal insulin in line with the daily
activity and needs of each patient.
Patients with CFRD report an increased risk of hypogly-
cemia (as a consequence of their impaired counter-regulatory
function or poor glucagon response [5,16]). In our patients,
the improvement in glycaemic control during the CSII
treatment did not lead to increase in severe hypoglycaemic
events. The use of only a rapid-acting insulin analogues and
a basal profile which better reflects the needs and the activity
of each patient are all factors which could help to prevent
episodes of hypoglycaemia.
As is also reported in type 1 diabetes [17,18], using the
insulin pump in our patients ,we have seen a significant
reduction in insulin requirements when compared with the
insulin requirements by the same patients when treated with
MDI therapy. Moran reports that little basal insulin is needed
in CFRD [10]. These data are not confirmed by our ex-
perience; indeed, in our patients the basal represents around
38–52% of the daily insulin requirement. The characteristics
of diabetes mellitus in CF differ from other forms of diabetes
both as regards the physiopathological and clinical aspects
and the management of the insulin therapy [16]. Our study is
limited to only three patients and is clear that more expe-
rience with the insulin pump in larger number of patients will
better clarify the characteristics and the differences of this
type of treatment.
Regarding the lipohypertrophy and the local cutaneous
infections at the insertion site of the cannula, which are
considered as risk factors in insulin pump therapy [19], in
our experience, we came across only two mild cases of
lipohypertrophy which were resolved by changing the in-
sertion site of the cannula and one episode of a mild local
240 N. Sulli et al. / Journal of Cystic Fibrosis 6 (2007) 237–240cutaneous infection which required no local antibiotic ther-
apy. However, we believe that these problems are easily
preventable by instructing the patient to abide by some
simple rules of hygiene and by alternating the insertion site
of the cannula.
In addition, insulin pump therapy offers the advantage of
fewer injections. The practical importance of this must not be
undervalued in patients with FC, who often have a busy and
complex daily treatment routine.
In conclusion, the use of CSII in our patients with CFRD
resulted in improvements in both the metabolic controls of
diabetes and the nutritional status with no concomitant
problems. There are some particulars concerning the use of
CSII in CFRD which regard the basal/bolus relationship and
the nocturnal basal quantity. Further studies with a larger
number of patients are required to evaluated the character-
istics and the specifics of CSII in patients with CFRD.
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